These findings establish a mechanistic link between BF treatment and EGFR pathway inhibition, demonstrating that BF antagonizes HCC progression by suppressing EGFR-mediated activation of the RAS-RAF-MEK-ERK axis. The gene discussed is RAF1; the disease is hepatocellular carcinoma.